Systemic Lupus Erythematosus Market Size Growing at 7% CAGR, Set to Reach USD 3,517 Million By 2030
March 01, 2023 10:00 ET
|
Acumen Research and Consulting
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- The Global Systemic Lupus Erythematosus Market Size accounted for USD 1,951 Million in 2021 and is estimated to achieve a market size of USD 3,517...
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
September 07, 2022 17:45 ET
|
Biogen Inc.
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to...
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
July 28, 2022 07:30 ET
|
Biogen Inc.
Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary...
Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight
February 09, 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key...
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
June 17, 2021 07:30 ET
|
Biogen Inc.
Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited...
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
April 20, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
October 08, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...
Global Systemic Lupus Erythematosus Market – Estimated to Gain Traction with Arrival of Key Pipeline Agents, with Promising Higher Efficacy than Existent Therapies - PMI
August 20, 2020 10:35 ET
|
PMI
Covina, CA, Aug. 20, 2020 (GLOBE NEWSWIRE) -- The report "Global Systemic Lupus Erythematosus Market, By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics),...
Systemic Lupus Erythematosus Market Size Worth Around USD 2.7 billion by 2026: Acumen Research and Consulting
February 21, 2019 11:00 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Systemic Lupus Erythematosus Market (By Drug Classes: NSAIDs, Corticosteroids,...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
September 26, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1st at 2:55 PM ET – – Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat...